OBJECTIVE: To explore the efficacy of carbon dioxide fractional laser combined with compound betamethasone in the treatment of vitiligo and its effects on Th17-related cytokines. METHODS: Totally 90 patients with vitiligo admitted into the hospital from Jan. 2018 to Jan. 2020 were extracted to be divided into the control group Ⅰ (carbon dioxide fractional laser), control group Ⅱ ( compound betamethasone) and combination therapy group (carbon dioxide fractional laser combined with compound betamethasone) via the random number table method, with 30 cases in each group. The efficacy and Th17-related cytokines were compared. RESULTS: There was no statistically significant difference in adverse drug reactions among the combination therapy group, control group Ⅰ and control group Ⅱ [13. 33%(4 / 30),10. 00%(3 / 30) and 6. 67%(2 / 30),P>0. 05]. Difference of recovery time of white spots on face-neck, limbs and hands-feet in combination therapy group, control group Ⅰ and control group Ⅱ was statistically significant (P<0. 05). The recovery time of white spots on face-neck, limbs and hands-feet in combination therapy group was significantly shorter than that in control group Ⅰ and control group Ⅱ, with statistically significant difference (P< 0. 05). After treatment, the levels of interleukin( IL)-17, IL-22 and IL-23 in combination therapy group, control group Ⅰ and control group Ⅱ had statistical significance (P<0. 05), and the levels of IL-17, IL-22 and IL-23 in combination therapy group were significantly lower than those in control group Ⅰ and control group Ⅱ, with statistically significant difference (P<0. 05). The effective rate of combination therapy group, control group Ⅰ and control group Ⅱ was respectively 90. 00% (27 / 30), 63. 33% (19 / 30) and 56. 67% (17 / 30), the effective rate of combination therapy group was significantly higher than that of control group Ⅰ and control group Ⅱ, with statistically significant difference ( P < 0. 05 ). CONCLUSIONS: The efficacy of carbon dioxide fractional laser combined with compound betamethasone in the treatment of vitiligo is significant, which can reduce the levels of serum Th17 cell related cytokines such as IL-17, IL-22 and IL-23. [ABSTRACT FROM AUTHOR]